Veeva Announces CRO Partnership Program and First Member - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Veeva Announces CRO Partnership Program and First Member

Source: Applied Clinical Trials

Veeva Systems announced that CRO Advanced Clinical both selected its Vault eTMF, and became the first member of its new partnership program. According to Julie Ross, Executive Vice President of Advanced Clinical, “A cloud-based eTMF gives us and our clients a strategic advantage. We can speed document collection from start-up through trial close, and our clients get the visibility they need throughout the entire study.” Through the Veeva CRO Partnership Program, Advanced Clinical received expert training and implementation support, and is prepared to deploy Vault eTMF for new and existing studies. Going forward, Advanced Clinical will receive regular checks and training on system updates. Also, as a CRO partner, they benefit from ongoing strategy sessions and Veeva’s marketing outreach.

Veeva Systems announced the new CRO partnership program to support growing trends in eTMF outsourcing and cloud adoption. In a recent Applied Clinical Trials article, http://bit.ly/I1prg6, the author observed that technology vendors are working closely with CROs in developing partner programs that benefit both the CRO as well as the sponsor. "Vendors have implemented strictly controlled, high quality training and testing programs along with user testing (certification), company accreditation and associated branding to recognize high quality CRO partners who are familiar with their technology.”

The full release can be read here.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
88%
Borrow lightly from EMA's pathway program?
4%
Create entirely its own pathway program?
8%
View Results
Untitled Document
Source: Applied Clinical Trials,
Click here